about
Launching invasive, first-in-human trials against Parkinson's disease: ethical considerationsThe community speaks: understanding ethical values in allocation of scarce lifesaving resources during disastersWhy clinical translation cannot succeed without failureCommentary: data monitoring confidentiality and FDA transparency.Equipoise, research stalemates, and the limits of new data.Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.Placebo use in vaccine trials: recommendations of a WHO expert panelImproving ethical review of research involving incentives for health promotion.Reviewing HIV-Related Research in Emerging Economies: The Role of Government Reviewing Agencies.Linguistic and Cultural Challenges in Communication and Translation in US-Sponsored HIV Prevention Research in Emerging EconomiesResearch ethics. Beyond access vs. protection in trials of innovative therapies.Ethical issues in haemophilia.Reasonable risks in clinical research: a critique and a proposal for the Integrative Approach.Incidental findings in the use of DNA to identify human remains: an ethical assessmentRisks of imbalanced information on US hospital websites.A non-paternalistic model of research ethics and oversight: assessing the benefits of prospective review.Position statement on ethics, equipoise and research on charged particle radiation therapy.Patient-Funded Trials: Opportunity or Liability?Benefit, Risk, and Outcomes in Drug Development: A Systematic Review of Sunitinib.Adversaries at the Bedside: Advance Care Plans and Future Welfare.Equipoise and international human-subjects research.Addressing ethical challenges in HIV prevention research with people who inject drugs.Public health. DNA identification after conflict or disaster.Clinical research in a public health crisis: the integrative approach to managing uncertainty and mitigating conflict.Research ethics. Rethinking research ethics: the case of postmarketing trials.The independence of practical ethics.Bringing science and advocacy together to address health needs of people who inject drugs.Equipoise in the enhanced supression of the platelet IIb/IIIa receptor with integrilin trial (ESPRIT): a critical appraisal.Is the concept of clinical equipoise still relevant to research?Equipoise in Research: Integrating Ethics and Science in Human Research.Assessing the Moral Coherence and Moral Robustness of Social Systems: Proof of Concept for a Graphical Models Approach.The Pluralism of Coherent Approaches to Global Health.The structure of clinical translation: efficiency, information, and ethics.Response to open peer commentaries on "The ethics of advertising for health care services".The ethics of advertising for health care services.Informative inducement: study payment as a signal of risk.Ethical considerations in the conduct of electronic surveillance research.How should we model rare disease allocation decisions?Learning health systems, clinical equipoise and the ethics of response adaptive randomisation.Research at the auction block: Problems for the fair benefits approach to international research.
P50
Q24289526-A2224E32-C75D-462E-9683-7C0FB53E2C2BQ28238812-0C4B853A-FF19-4984-85F8-C59DC8F8A7EAQ28607112-51919ED3-A484-49A5-9FD6-DB368FC8BEE7Q30881108-3EDC6B89-517E-49DE-9515-34438FC28276Q33825374-BFE64164-6011-474C-A23D-1AFC9A06FE67Q33851241-7D2C2427-0B69-4243-B4B2-79174917CD6FQ34147558-69BFFC8C-C06F-4708-B0CA-CAF306172441Q34220895-09D0352D-EDBA-47CC-8DAE-1F09FD948542Q35589584-AA9E1E61-2945-4BC6-BE1A-6EF679CD2460Q35726024-0C825464-5FB8-46E5-93E0-4D2941E4389BQ35893072-74D2BF5B-739B-479F-B947-39CFE1E77701Q36473033-A4227E09-CDDB-4A0A-98D5-E1AEE57BA8C9Q36524106-3E89BD88-BFCB-4D15-86B8-84B19C2607F4Q36636714-0C2F9BAB-1C54-4BAE-8906-32182842E4D7Q36909152-DDF1A6E4-74D7-46DA-8678-2A991A8413EFQ38071677-84076988-CC8B-4E5B-B6F2-4AD8ACB6E826Q38138821-5EC989B4-91C9-4268-882A-7A6A797250D8Q38562564-1301E79A-6460-458C-A859-64641D6A0486Q38627885-32655988-E5F9-4E14-AC05-A580155EDA8EQ38863901-D624C59C-FDA8-4C93-803E-F602489A9F83Q38884845-FDDA7655-6471-4D4C-9532-D6D4BA30EC86Q40699304-956177F6-C50F-4D08-BE79-E8F03A430836Q41967275-230D6D0E-10DE-4FE8-B8F7-BC58B81CBB5BQ41998852-278F0FEA-2729-48FE-B845-046F066F2B40Q42395022-C6E79FE7-6581-46DA-9514-22CA818AB7C8Q43661725-74DCA3BF-8334-412A-9D05-1DB2BE6B1340Q46297697-84992D50-B6DD-4522-BBA3-03599298F735Q46797749-7DB2AF20-C169-45B4-BBCD-6043A0AF5889Q47568523-1203BA6C-08B2-404D-8171-E74831D61DC1Q47577966-1DB6E7A0-69A4-410F-B200-46B826601764Q47638680-EC647B79-E00E-48EF-A5AA-32CA4507E77BQ47682360-C38BC380-5CCF-42A8-81E6-B02559BBBCA4Q48051735-F3AA9506-7923-41C4-B740-D450D3EC412FQ48079898-4AE0E38E-923C-4ABD-BFD4-DBAD8B584BE5Q48084161-40CCE528-FE16-4FE5-85F4-D53AF608A2DAQ48246395-3ADA80EC-41E8-416C-8829-574A8BEB41A9Q48422246-2034E276-3FDC-4A9E-B4F4-4176269942FFQ48438970-05D92DE3-2F4A-4C67-B085-FB91A8C2D445Q49628915-B48AE691-80A8-4BF7-B80D-51D73DC323C0Q53067275-12B89C0B-414F-4073-920D-CC1326D7C954
P50
description
ethicus
@nl
hulumtues
@sq
researcher
@en
հետազոտող
@hy
name
Alex John London
@ast
Alex John London
@en
Alex John London
@es
Alex John London
@nl
type
label
Alex John London
@ast
Alex John London
@en
Alex John London
@es
Alex John London
@nl
prefLabel
Alex John London
@ast
Alex John London
@en
Alex John London
@es
Alex John London
@nl
P101
P1153
7005248959
P21
P31
P496
0000-0002-6450-0309